These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 28482719)
1. MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy. Colomer-Lahiguera S; Pisecker M; König M; Nebral K; Pickl WF; Kauer MO; Haas OA; Ullmann R; Attarbaschi A; Dworzak MN; Strehl S Leuk Lymphoma; 2017 Dec; 58(12):2895-2904. PubMed ID: 28482719 [TBL] [Abstract][Full Text] [Related]
2. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Zuurbier L; Gutierrez A; Mullighan CG; Canté-Barrett K; Gevaert AO; de Rooi J; Li Y; Smits WK; Buijs-Gladdines JG; Sonneveld E; Look AT; Horstmann M; Pieters R; Meijerink JP Haematologica; 2014 Jan; 99(1):94-102. PubMed ID: 23975177 [TBL] [Abstract][Full Text] [Related]
3. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression? Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269 [TBL] [Abstract][Full Text] [Related]
4. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Homminga I; Pieters R; Langerak AW; de Rooi JJ; Stubbs A; Verstegen M; Vuerhard M; Buijs-Gladdines J; Kooi C; Klous P; van Vlierberghe P; Ferrando AA; Cayuela JM; Verhaaf B; Beverloo HB; Horstmann M; de Haas V; Wiekmeijer AS; Pike-Overzet K; Staal FJ; de Laat W; Soulier J; Sigaux F; Meijerink JP Cancer Cell; 2011 Apr; 19(4):484-97. PubMed ID: 21481790 [TBL] [Abstract][Full Text] [Related]
5. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. La Starza R; Barba G; Demeyer S; Pierini V; Di Giacomo D; Gianfelici V; Schwab C; Matteucci C; Vicente C; Cools J; Messina M; Crescenzi B; Chiaretti S; Foà R; Basso G; Harrison CJ; Mecucci C Haematologica; 2016 Aug; 101(8):951-8. PubMed ID: 27151989 [TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia. Demina I; Dagestani A; Borkovskaia A; Semchenkova A; Soldatkina O; Kashpor S; Olshanskaya Y; Roumiantseva J; Karachunskiy A; Novichkova G; Maschan M; Zerkalenkova E; Popov A Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891797 [TBL] [Abstract][Full Text] [Related]
7. Copy Number Alterations in CDKN2A/2B and MTAP Genes Are Associated With Low MEF2C Expression in T-cell Acute Lymphoblastic Leukemia. Kumari S; Singh J; Arora M; Ali MS; Pandey AK; Benjamin M; Palanichamy JK; Bakhshi S; Qamar I; Chopra A Cureus; 2022 Dec; 14(12):e32151. PubMed ID: 36601176 [TBL] [Abstract][Full Text] [Related]
8. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Bardelli V; Arniani S; Pierini V; Di Giacomo D; Pierini T; Gorello P; Mecucci C; La Starza R Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440292 [TBL] [Abstract][Full Text] [Related]
9. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924 [TBL] [Abstract][Full Text] [Related]
10. High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage. Schraders M; van Reijmersdal SV; Kamping EJ; van Krieken JH; van Kessel AG; Groenen PJ; Hoogerbrugge PM; Kuiper RP Cancer Genet Cytogenet; 2009 May; 191(1):27-33. PubMed ID: 19389505 [TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characteristics of Ohki K; Kiyokawa N; Saito Y; Hirabayashi S; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fukushima K; Hasegawa D; Fukushima H; Imai M; Kajiwara R; Koike T; Komori I; Matsui A; Mori M; Moriwaki K; Noguchi Y; Park MJ; Ueda T; Yamamoto S; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Takahashi H; Fukushima T; Hayashi Y; Koh K; Manabe A; Ohara A; Haematologica; 2019 Jan; 104(1):128-137. PubMed ID: 30171027 [TBL] [Abstract][Full Text] [Related]
14. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB. Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415 [TBL] [Abstract][Full Text] [Related]
15. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643 [TBL] [Abstract][Full Text] [Related]
16. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. Wang HP; Zhou YL; Huang X; Zhang Y; Qian JJ; Li JH; Li XY; Li CY; Lou YJ; Mai WY; Meng HT; Yu WJ; Tong HY; Jin J; Zhu HH Am J Hematol; 2021 Mar; 96(3):312-319. PubMed ID: 33306218 [TBL] [Abstract][Full Text] [Related]
17. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Remke M; Pfister S; Kox C; Toedt G; Becker N; Benner A; Werft W; Breit S; Liu S; Engel F; Wittmann A; Zimmermann M; Stanulla M; Schrappe M; Ludwig WD; Bartram CR; Radlwimmer B; Muckenthaler MU; Lichter P; Kulozik AE Blood; 2009 Jul; 114(5):1053-62. PubMed ID: 19406988 [TBL] [Abstract][Full Text] [Related]
18. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup. Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494 [TBL] [Abstract][Full Text] [Related]
19. DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma. Haider Z; Landfors M; Golovleva I; Erlanson M; Schmiegelow K; Flægstad T; Kanerva J; Norén-Nyström U; Hultdin M; Degerman S Blood Cancer J; 2020 Apr; 10(4):45. PubMed ID: 32345961 [TBL] [Abstract][Full Text] [Related]
20. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]